Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 7/2022

25-05-2022 | Tuberculosis | Original Article

Use of DosR and Rpf antigens from Mycobacterium tuberculosis to screen for latent and relapse tuberculosis infection in a tuberculosis endemic community of Huainan City

Authors: Lirong Mao, Lifa Xu, Xiaochun Wang, Jianpeng Du, Qishan Sun, Zilun Shi, Jian Wang, Yingru Xing, Yixing Su, Ying Xu, Zhiyang Qi, Lu Xia, Jilei Ma, Jingyan Zhang

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 7/2022

Login to get access

Abstract

The dormancy survival regulator (DosR) antigens upgraded during latency and resuscitation-promoting factors (Rpfs) expressed over the reactivation from dormant Mycobacterium tuberculosis (M. tuberculosis) could be used to diagnose tuberculosis (TB) at different stages. We performed a retrospective cohort study based on four groups, including healthy controls (HCs), active tuberculosis infections (ATBs), latent tuberculosis infections (LTBIs), and relapse tuberculosis infections (RTBs) enrolled between November 2020 and June 2021. Compared to the fusion protein E6-C10, combined with early secreted antigenic target 6 kDa (ESAT-6) and culture filtrate of 10 kDa (CFP-10), the DosR- or Rpf-encoded antigens could not elicit significant IFN-γ concentration for the diagnosis of ATB. Of note, the DosR antigens produce significantly more antigen-specific IFN-γ in LTBIs than Rpfs, and the levels of antigen-specific IFN-γ elicited in RTBs stimulated by Rpfs were higher than the DosR antigens. Among the DosR antigens, Rv2003c was the most immunogenic in diagnosing LTBIs, followed by Rv2007c and Rv2005c. As far as Rpfs are concerned, Rv0867c was the best antigen to identify RTBs, followed by Rv2389c and Rv1009. Both Rv2450c and Rv1884c showed relatively limited IFN-γ concentration in RTBs. Besides, the selected DosR antigens and Rpfs showed ideal specificity and inadequate sensitivity, which could have been enhanced by the fusion antigens prepared by the DosR antigens or Rpfs, respectively. The results of this study can provide more accurate detection methods for LTBIs and RTBs and could be used for screening the dormant M. tuberculosis throughout reactivation.
Appendix
Available only for authorised users
Literature
22.
go back to reference Arroyo L, Rojas M, Ortíz BL, Franken KL, García LF, Ottenhoff TH et al (2016) Dynamics of the T cell response to Mycobacterium tuberculosis DosR and Rpf antigens in a Colombian population of household contacts of recently diagnosed pulmonary tuberculosis patients. Tuberculosis (Edinb) 97:97–107. https://doi.org/10.1016/j.tube.2015.12.008CrossRef Arroyo L, Rojas M, Ortíz BL, Franken KL, García LF, Ottenhoff TH et al (2016) Dynamics of the T cell response to Mycobacterium tuberculosis DosR and Rpf antigens in a Colombian population of household contacts of recently diagnosed pulmonary tuberculosis patients. Tuberculosis (Edinb) 97:97–107. https://​doi.​org/​10.​1016/​j.​tube.​2015.​12.​008CrossRef
23.
25.
39.
go back to reference Rao S, Rahim M, Iqbal K, Haroon F, Hasan Z (2019) Impact of diabetes on mechanisms of immunity against Mycobacterium tuberculosis. J Pak Med Assoc 69(1):94–98PubMed Rao S, Rahim M, Iqbal K, Haroon F, Hasan Z (2019) Impact of diabetes on mechanisms of immunity against Mycobacterium tuberculosis. J Pak Med Assoc 69(1):94–98PubMed
Metadata
Title
Use of DosR and Rpf antigens from Mycobacterium tuberculosis to screen for latent and relapse tuberculosis infection in a tuberculosis endemic community of Huainan City
Authors
Lirong Mao
Lifa Xu
Xiaochun Wang
Jianpeng Du
Qishan Sun
Zilun Shi
Jian Wang
Yingru Xing
Yixing Su
Ying Xu
Zhiyang Qi
Lu Xia
Jilei Ma
Jingyan Zhang
Publication date
25-05-2022
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 7/2022
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-022-04459-8

Other articles of this Issue 7/2022

European Journal of Clinical Microbiology & Infectious Diseases 7/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.